

CLINICAL DEVELOPMENT OF DIAMYD'S PRODUCTS

Product	Phase & Country	Year initiated	Participants	Age, years	Number of patients	Trial period	Purpose
Diamyd®	Skin prick test, Sweden	1995	Type 1 diabetes patients and healthy individuals	Adolescents	N=15	28 days	Safety
Diamyd®	Phase I, UK	1999	Healthy individuals	24–45	N=24	10 weeks	Safety and tolerability
Diamyd® for LADA	Phase IIa, Sweden	2000	LADA patients	30–70	N=47	Trial period: 6 months. Follow-up: 5 years. Completed.	Dose-finding, safety and efficacy
Diamyd® for type 1	Phase IIb, Sweden	2004	Type 1 diabetes patients	10–18	N=70	Trial period: 15 months. Follow-up: 15 months. Completed.	Safety and efficacy
Diamyd® for LADA	Phase IIb, Sweden	2004	LADA patients	30–70	N=160	Trial period: 18 months. Follow-up: 12 months. Completed.	Safety
Diamyd® for type 1	Phase III, Europe	2008	Type 1 diabetes patients	10–20	N=320	Trial period: 15 months. Follow-up: 15 months. In progress.	Safety and efficacy
Diamyd® for type 1	Phase III, USA	2008	Type 1 diabetes patients	10–20*	N=320	Trial period: 15 months. Follow-up: 15 months. In progress.	Safety and efficacy
NP2	Phase I, USA	2008	Cancer patients	Adults	N=12	Trial period: 4 months per dose group. In progress.	Safety and efficacy

NP2	Phase I, USA	2008	Cancer patients	Adults	N=12	Trial period: 4 months per dose group. In progress.	Safety and efficacy
Diamyd® for type 1	Phase III, USA	2008	Type 1 diabetes patients	10–20*	N=320	Trial period: 15 months. Follow-up: 15 months. In progress.	Safety and efficacy
Diamyd® for type 1	Phase III, Europe	2008	Type 1 diabetes patients	10–20	N=320	Trial period: 15 months. Follow-up: 15 months. In progress.	Safety and efficacy
Diamyd® for LADA	Phase IIb, Sweden	2004	LADA patients	30–70	N=160	Trial period: 18 months. Follow-up: 12 months. Completed.	Safety

*Stepwise lowering of age